Medicago Inc. (MDCGF)
-OTC Markets 0.72 
0.02(3.01%) May 24, 11:35AM EDT
| Prev Close: | 0.70 |
|---|
| Open: | 0.72 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.72 - 0.72 |
|---|
| 52wk Range: | 0.35 - 0.76 |
|---|
| Volume: | 397 |
|---|
| Avg Vol (3m): | 14,038 |
|---|
| Market Cap: | 178.80M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.14 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Medicago Announces 2013 First Quarter Financial ResultsCNW Group(Thu, May 9)
- Medicago Announces 2013 First Quarter Financial ResultsPR Newswire(Thu, May 9)
- Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in ChinaPR Newswire(Wed, May 8)
- Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in ChinaCNW Group(Wed, May 8)
- Medicago Announces a $3.5 Million Private PlacementCNW Group(Tue, Apr 23)
- Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 VaccinePR Newswire(Wed, Apr 17)
- Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 VaccineCNW Group(Wed, Apr 17)
- MEDICAGO INC. FinancialsEDGAR Online Financials(Tue, Apr 9)
- Medicago and IDRI to present data at the World Vaccine CongressCNW Group(Tue, Apr 9)
- Medicago and IDRI to present data at the World Vaccine CongressPR Newswire(Tue, Apr 9)
- IDRI and Medicago to present data at the World Vaccine CongressPR Newswire(Tue, Apr 9)
- Medicago Announces 2012 Fourth Quarter and Year-End Financial ResultsCNW Group(Thu, Mar 28)
- Medicago Announces 2012 Fourth Quarter and Year-End Financial ResultsPR Newswire(Thu, Mar 28)
- Medicago Invited to Present at Upcoming U.S. Investor ConferencesCNW Group(Tue, Feb 26)
- Medicago Invited to Present at Upcoming U.S. Investor ConferencesPR Newswire(Tue, Feb 26)
Reports
- No Reports available for MDCGF at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 30.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide.
View More